Navigation Links
Kendle Leaders Adopt 10b5-1 Trading Plans
Date:3/7/2008

CINCINNATI, March 7 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Chairman and Chief Executive Officer Candace Kendle, PharmD, and President and Chief Operating Officer Chris Bergen have established prearranged trading plans to sell shares of the company's common stock over a designated period. The stock trading plans are part of their personal ongoing long-term strategy for tax planning and asset diversification and were adopted in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934 and Kendle's policy regarding stock transactions by its insiders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Under the trading plans, during a six-month period commencing March 20, 2008, and ending Sept. 30, 2008, Dr. Kendle and Mr. Bergen plan to sell up to 550,715 and 302,136 shares of KNDL common stock, respectively, in open market transactions. Transactions under this plan will be disclosed publicly by Dr. Kendle and Mr. Bergen through Securities and Exchange Commission filings.

Rule 10b5-1 permits insiders to implement a written plan to sell stock when they are not in possession of material non-public information and continue to sell shares on a regular basis even if they receive such information subsequently. Such plans establish predetermined trading parameters that do not permit the person adopting the plan to exercise any subsequent influence over how, when, or whether to affect trades. Using these plans, insiders can gradually diversify their investment portfolios, spread stock trades out over an extended period of time to reduce market impact, and avoid concerns about transactions occurring at a time when they might possess inside information.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip. Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
2. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
3. Kendle to Present at the Wachovia 2008 Healthcare Conference
4. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
5. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
6. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
7. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
8. Kendle to Present at the UBS Global Life Sciences Conference
9. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
10. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the world’s first ... new and improved ways of treating coronary artery disease (CAD). Lam is an ...
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
(Date:3/24/2017)... March 24, 2017 MiMedx Group, Inc. (NASDAQ: ... human placental tissue allografts and patent-protected processes to develop ... of healthcare, announced today  that it will present at ... , NY.  Parker H. "Pete" Petit, Chairman and ... Christopher M. Cashman , EVP and Chief Commercialization ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... - Global Strategic Business Report" report to their offering. ... This report analyzes ... US$ Million. Annual estimates and forecasts are provided for the period ... and secondary research. The report profiles 25 companies ...
Breaking Biology Technology:
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... 2017 PMD Healthcare announces the release of ... Management System (WMS), a remote, real-time lung health monitoring ... Healthcare is a Medical Device, Digital Health, and Chronic ... creating innovative solutions that empower people to improve their ... PMD developed the first ever personal spirometer, Spiro PD, ...
Breaking Biology News(10 mins):